BioMarin Pharmaceutical Inc. (BMRN) Q2 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for joining BioMarine's second quarterly results conference call. Hosting today's call from BioMarine is Tracey McCarthy, Head of Investor Relations at BioMarine. Please go ahead, Tracey. Thank you, JP, and thank you, everyone, for joining us today. To remind you, this non-confidential presentation contains forward-looking statements about the business prospects of BioMarine Pharmaceutical Inc., including expectations regarding BioMarine's financial performance, commercial products, and potential future products in different areas of therapeutic research and development. Results may differ materially depending on the progress of Biomarin's product programs, actions of regulatory authorities, availability of capital, future actions in the pharmaceutical market, and developments by competitors. And those factors detail in Biomarin's filings with Securities and Exchange Commission, such as 10Q, 10K, and 8K reports. On the call from Biomarin's management team today are JJ Bien-Aimé, Chairman and Chief Executive Officer, Jeff Ager, Executive Vice President, Chief Commercial Officer, Hank Fuchs, President, Worldwide Research and Development, Greg Geyer, Executive Vice President, Commercial Chief Technical Officer, Brian Mueller, Executive Vice President, and Chief Financial Officer. I will now turn the call over to Biomarin's Chairman and CEO, JJ Bien-Aimé. Thank you, Tracy, and good afternoon, everyone. Thank you for joining us today on this call. We were very pleased with our progress in the second quarter as more families around the world gained access to VoxOgo and the highly anticipated FE approval of Roktavion was received. The achievement of these two milestones are key components of our growth plans, including continued VoxOgo expansion and Roktavion laun...